Format

Send to

Choose Destination
Clin Transl Sci. 2019 Nov 23. doi: 10.1111/cts.12729. [Epub ahead of print]

Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.

Author information

1
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
2
Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
3
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
4
Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
5
UF Health & UF Health Sciences Center, Gainesville, Florida, USA.
6
Division of Cardiology, Department of Medicine, University of Florida, Jacksonville, Florida, USA.
7
Bioinformatics Core, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, Florida, USA.
8
Epidemiology, University of Florida, Gainesville, Florida, USA.
9
Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.

Abstract

We aimed to estimate the utility of panel-based pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI). Utilization of Clinical Pharmacogenetic Implementation Consortium (CPIC) level A/B drugs after PCI was estimated in a national sample of IBM MarketScan beneficiaries. Genotype data from University of Florida (UF) patients (n = 211) who underwent PCI were used to project genotype-guided opportunities among MarketScan beneficiaries with at least one (N = 105,547) and five (N = 12,462) years of follow-up data. The actual incidence of genotype-guided prescribing opportunities was determined among UF patients. In MarketScan, 50.0% (52,799/105,547) over 1 year and 68.0% (8,473/12,462) over 5 years had ≥ 1 CPIC A/B drug besides antiplatelet therapy prescribed, with a projected incidence of genotype-guided prescribing opportunities of 39% at 1 year and 52% at 5 years. Genotype-guided prescribing opportunities occurred in 32% of UF patients. Projected and actual incidence of genotype-guided opportunities among two cohorts supports the utility of panel-based testing among patients who underwent PCI.

PMID:
31758664
DOI:
10.1111/cts.12729

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center